Foxy-5 TFA

发表于由

Foxy-5 TFA; 纯度: 99.10%

Foxy-5 TFA 是 WNT5A 激动剂，是 WNT5A 的一个模拟肽，是 Wnt 家族的非经典成员。Foxy-5 TFA 可在不影响 β-catenin 激活的情况下触发胞浆游离钙信号传导，并可抑制上皮癌细胞的迁移和侵袭。Foxy-5 TFA 在原位小鼠模型中能有效降低 WNT5A 低表达的前列腺癌细胞的转移扩散。

Foxy-5 TFAamp;;

Foxy-5 TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ￥1200 In-stock
5 mg ￥3900 In-stock
10 mg ; 询价 ;
50 mg ; 询价 ;

* Please select Quantity before adding items.

Foxy-5 TFA 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model[1][2][3][4].

IC50 Target

WNT5A[1]
体内研究
(In Vivo)

Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model[1].
Foxy-5 reduces the number of colonic cancer stem cells in a xenograft mouse model of human colonic cancer[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

808.80

Formula

C28H43F3N6O14S2
Sequence Shortening

MDGCEL
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro:;

H2O : 20 mg/mL (24.73 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2364 mL 6.1820 mL 12.3640 mL
5 mM 0.2473 mL 1.2364 mL 2.4728 mL
10 mM 0.1236 mL 0.6182 mL 1.2364 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Säfholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14(20):6556-63.

    [2]. Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39(4):1719-1728.

    [3]. Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12(9):e0184418.

    [4]. Kelsey R. Prostate cancer: Foxy-5 in prostate cancer model. Nat Rev Urol. 2017 Nov;14(11):638.